![Matthew Klein](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Matthew Klein
Algemeen Directeur bij
PTC THERAPEUTICS, INC.
Vermogen: 33 M $ op 30-06-2026
Profiel
Dr. Matthew B. Klein, MD, is an Independent Director at ClearPoint Neuro, Inc., a President, Chief Executive Officer & Director at PTC Therapeutics, Inc. and a Clinical Associate Professor at Stanford University.
He is on the Board of Directors at ClearPoint Neuro, Inc., PTC Therapeutics, Inc. and PTC Therapeutics International Ltd. Dr. Klein was previously employed as a Chief Medical Officer by BioElectron Technology Corp., a Chief Medical Officer & Senior Vice President by Edison Pharmaceuticals, Inc., and a Chairman-Restorative Burn Surgery by University of Washington.
He received his undergraduate degree from the University of Pennsylvania, a graduate degree from UW School of Public Health and a doctorate degree from Yale University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 14-05-2026 | 393.998 ( 0,47% ) | 32 M $ | 30-06-2026 | |
| 21-05-2026 | 46.935 ( 0,16% ) | 837 320 $ | 30-06-2026 |
Actieve functies van Matthew Klein
| Bedrijven | Functie | Begin |
|---|---|---|
| CLEARPOINT NEURO, INC. | Directeur/Bestuurslid | 16-04-2020 |
| PTC THERAPEUTICS, INC. | Algemeen Directeur | 22-03-2023 |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
PTC Therapeutics International Ltd.
 PTC Therapeutics International Ltd. PTC Therapeutics International Ltd. is an Irish biopharmaceutical company focused on discovering, developing, and commercializing therapies for rare diseases with high unmet medical needs. The company is based in DU. The company addresses the root causes of serious genetic, metabolic, and neurological conditions through approaches such as RNA splicing modulation and targeting oxidative stress and inflammation pathways, particularly in central nervous system disorders. Its therapeutic portfolio and pipeline include treatments for rare diseases such as phenylketonuria (PKU), aromatic l-amino acid decarboxylase (AADC) deficiency, Duchenne muscular dystrophy (DMD), hereditary transthyretin amyloidosis (hATTR), familial partial lipodystrophy (FPL), spinal muscular atrophy (SMA), and Friedreich’s ataxia. PTC collaborates with partners to bring treatments to market and supports patients, caregivers, and healthcare providers through educational programs and personalized assistance. The company conducts clinical trials and investigator-initiated studies, maintains dedicated patient engagement teams, and emphasizes corporate responsibility, compliance, and transparency with investors. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Matthew Klein
| Bedrijven | Functie | Einde |
|---|---|---|
BioElectron Technology Corp.
 BioElectron Technology Corp. Miscellaneous Commercial ServicesCommercial Services Develops therapeutic treatments for inherited mitochondrial diseases primarily affecting children | Algemeen Directeur | 01-01-2019 |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Edison Pharmaceuticals, Inc.
 Edison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs to treat mitochondrial diseases | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Matthew Klein
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
61
Eerstegraads connecties
10
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 10 |
|---|---|
PTC Therapeutics, Inc.
 PTC Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets clinically differentiated medicines for neurodegenerative diseases | Health Technology |
Edison Pharmaceuticals, Inc.
Edison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs to treat mitochondrial diseases | Health Technology |
Stanford University
Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Washington
University of Washington Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Pennsylvania
 University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Clearpoint Neuro, Inc.
 Clearpoint Neuro, Inc. Medical SpecialtiesHealth Technology Develops and markets bio technology and surgical products | Health Technology |
PTC Therapeutics International Ltd.
PTC Therapeutics International Ltd. PTC Therapeutics International Ltd. is an Irish biopharmaceutical company focused on discovering, developing, and commercializing therapies for rare diseases with high unmet medical needs. The company is based in DU. The company addresses the root causes of serious genetic, metabolic, and neurological conditions through approaches such as RNA splicing modulation and targeting oxidative stress and inflammation pathways, particularly in central nervous system disorders. Its therapeutic portfolio and pipeline include treatments for rare diseases such as phenylketonuria (PKU), aromatic l-amino acid decarboxylase (AADC) deficiency, Duchenne muscular dystrophy (DMD), hereditary transthyretin amyloidosis (hATTR), familial partial lipodystrophy (FPL), spinal muscular atrophy (SMA), and Friedreich’s ataxia. PTC collaborates with partners to bring treatments to market and supports patients, caregivers, and healthcare providers through educational programs and personalized assistance. The company conducts clinical trials and investigator-initiated studies, maintains dedicated patient engagement teams, and emphasizes corporate responsibility, compliance, and transparency with investors. | |
BioElectron Technology Corp.
BioElectron Technology Corp. Miscellaneous Commercial ServicesCommercial Services Develops therapeutic treatments for inherited mitochondrial diseases primarily affecting children | Commercial Services |
UW School of Public Health
 UW School of Public Health Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
